Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desfesoterodine is a small molecule antimuscarinic agent used in the symptomatic treatment of urinary frequency and incontinence. It acts as a competitive antagonist at muscarinic acetylcholine receptors, particularly those in the bladder, leading to relaxation of bladder smooth muscle and reduction of involuntary contractions. Desfesoterodine is the active metabolite of fesoterodine and also a known human metabolite of tolterodine. Its primary indication is for overactive bladder symptoms such as urgency, frequency, and urge incontinence[8][9][2]. The drug has been investigated for use via intravenous administration[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desfesoterodine.